CHRS Coherus BioSciences, Inc.

20.20
-0.20  -1%
Previous Close 20.40
Open 20.50
Price To book 13.39
Market Cap 1.04B
Shares 51,288,000
Volume 432,999
Short Ratio 7.63
Av. Daily Volume 562,162

SEC filingsSee all SEC filings

  1. 8-K - Current report 17857784
  2. 8-K - Current report 17839391
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822426
  4. 8-K - Current report 17822226
  5. 8-K - Current report 17781120

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing due towards the end of 2Q 2017.
CHS-1420
Psoriasis
PDUFA date June 9, 2017.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. [$$] AbbVie: It's the Pipeline, Not the Coherus Ruling
  2. AbbVie Down on Humira Patent Loss: Is More Damage in Store?
  3. AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech
  4. Why This Humira Patent Loss Might Not Be What You Think
  5. AbbVie Stock Lower on Humira Patent Ruling
  6. Coherus BioSciences Prevails in ‘135 IPR Decision
  7. Edited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT
  8. Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : May 12, 2017
  9. Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock?
  10. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : May 11, 2017
  11. Coherus BioSciences reports 1Q loss
  12. Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
  13. Investor Network: Coherus BioSciences, Inc. to Host Earnings Call
  14. The Prospects For CHS-3351, Coherus' Most Underappreciated Asset
  15. Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
  16. ETFs with exposure to Coherus BioSciences, Inc. : April 25, 2017
  17. Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
  18. Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
  19. Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development